Thrombocytosis
Showing 1 - 25 of 529
Molecular Biology of Polycythemia and Thrombocytosis
Recruiting
- Polycythemia
- Thrombocytosis
-
Salt Lake City, UtahUniversity of Utah
Dec 28, 2022
Myelodysplastic/Myeloproliferative Tumor With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Tumor,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Hydroxyurea
- Luspatercept
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 6, 2023
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis Trial in Houston
Completed
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 27, 2022
The Role of Circ0014614 in the Formation and Development of ET
Recruiting
- Primary Thrombocytosis
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Jun 18, 2023
Myeloproliferative Tumor, Polycythemia Vera, Essential Thrombocythemia Trial in Hong Kong
Recruiting
- Myeloproliferative Neoplasm
- +7 more
-
Hong Kong, Hong KongDepartment of Medicine, Queen Mary Hospital
May 21, 2023
Myeloproliferative Tumor, MPN, Essential Thrombocythemia Trial in Orange (N-Acetylcysteine)
Active, not recruiting
- Myeloproliferative Neoplasm
- +4 more
-
Orange, CaliforniaChao Family Comprehensive Cancer Center, University of Californi
Jan 6, 2023
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Not yet recruiting
- Myelofibrosis (PMF)
- +2 more
-
New York, New YorkRuttenberg Treatment Center
Apr 18, 2023
Essential Thrombocythemia Trial (Ropeginterferon alfa-2b-njft (P1101))
Not yet recruiting
- Essential Thrombocythemia
- Ropeginterferon alfa-2b-njft (P1101)
- (no location specified)
Jul 28, 2022
Myeloproliferative Tumor, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage Trial (CALR allele burden
Recruiting
- Myeloproliferative Neoplasm
- +3 more
- CALR allele burden quantification
-
Angers, FranceCHU Angers
Nov 2, 2022
Myelofibrosis, Essential Thrombocythemia, MPN Trial in New York (Peptide-based vaccine, Poly ICLC)
Not yet recruiting
- Myelofibrosis
- +2 more
- Peptide-based vaccine
- Poly ICLC
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Jun 7, 2022
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF Trial in New York (Canakinumab)
Recruiting
- Primary Myelofibrosis
- +4 more
-
New York, New YorkRuttenberg Treatment Center
Jul 18, 2022
Essential Thrombocytopenia Trial in Tianjin (Recombinant Interferon Alpha, Pegylated interferon alfa-2b)
Recruiting
- Essential Thrombocytopenia
- Recombinant Interferon Alpha
- Pegylated interferon alfa-2b
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jul 18, 2022
Polycythemia Vera, Essential Thrombocythemia, and
Not yet recruiting
- Myeloproliferative Neoplasm
- Next-generation sequencing
- (no location specified)
Jun 27, 2022
A Prospective, Two-arm, Non-interventional Study of JAKAVI® in
Active, not recruiting
- Primary Myelofibrosis
- +2 more
- Jakavi
-
Aachen, GermanyNovartis Investigative Site
Sep 6, 2021
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +3 more
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia Trial in Toronto (Observational)
Recruiting
- Primary Myelofibrosis
- +9 more
- Observational
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 11, 2022
Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis Trial in Buffalo (drug, dietary supplement, other)
Terminated
- Essential Thrombocythemia
- +2 more
- Arsenic Trioxide
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2022
Myeloproliferative Tumor, Essential Thrombocythemia, JAK2 Mutation Trial in Ottawa (Apixaban 2.5 MG Oral Tablet [ELIQUIS],
Recruiting
- Myeloproliferative Neoplasm
- +5 more
- Apixaban 2.5 MG Oral Tablet [ELIQUIS]
- Aspirin 81 mg
-
Ottawa, Ontario, CanadaThe Ottawa Hospital
Apr 19, 2022